Monitor for any definitive agreement on an acquisition or in-licensing transaction, which would be the primary catalyst for this stock. Absent a deal, the stock is likely to trade on cash runway and general biotech sentiment — no near-term operational catalyst exists.
Price Chart
Executive Summary
Instil Bio reported Q2 2026 results with a GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, driven by sharply lower operating expenses as the company maintains a lean cash-burn structure while evaluating acquisition and in-licensing opportunities. Cash and marketable securities stood at $69.9M, down from $76.3M at year-end 2025, but management expects this to fund operations beyond 2027. The filing is routine for a pre-revenue biotech with no pipeline catalysts — the stock's direction hinges entirely on whether a transaction materializes, not on the quarterly loss trajectory.
Key Financial Metrics
Key Facts
- GAAP net loss per share was $0.63 for Q2 2026, vs $3.24 in Q2 2025
- Cash, cash equivalents, restricted cash and marketable securities totaled $69.9M as of June 30, 2026
- Cash runway expected to fund operating plan beyond 2027
- R&D expenses fell to $0.3M in Q2 2026 from $6.7M in Q2 2025
- G&A expenses fell to $5.1M in Q2 2026 from $6.2M in Q2 2025
- No in-process R&D expenses in Q2 2026 vs $10.0M in Q2 2025
- Company is evaluating potential acquisitions, in-licensing and related opportunities
- No revenue reported; company is pre-revenue
Financial Impact
Net loss of $4.3M in Q2 2026 vs $21.4M in Q2 2025; cash burn of ~$6.4M in H1 2026
Risk Factors
- No pipeline assets or revenue-generating operations — company is a cash shell seeking a transaction
- Cash burn continues at ~$3-4M per quarter, reducing the acquisition currency over time
- No guarantee that a suitable acquisition or in-licensing opportunity will be identified or consummated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001789769-26-000055 |
| Document: til-20260813.htm | 0001789769-26-000055 |
| Document: 0001789769-26-000055-index-headers.html | 0001789769-26-000055 |
| Document: 0001789769-26-000055-index.html | 0001789769-26-000055 |
| Document: 0001789769-26-000055.txt | 0001789769-26-000055 |
| 8-K Data (Synthetic) | 0001789769-26-000055 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | Press Release | $7.38 $7.45 | ▲ +0.95% | ▲ +2.94% | $7.38 (+0.00%) |
Aug 13, 2026 7w ago | 8-K | $7.38 $7.45 | ▲ +0.95% | ▲ +2.94% | $7.38 (+0.00%) |
May 15, 2026 20w ago | 8-K | $8.07 $7.92 | ▼ −1.86% | ▼ −3.98% | $7.38 (−8.55%) |
May 15, 2026 20w ago | Press Release | $8.07 $7.92 | ▼ −1.86% | ▼ −3.98% | $7.38 (−8.55%) |
Apr 24, 2026 22w ago | DEFA14A | $8.13 $8.12 | ▼ −0.12% | ▼ −5.08% | $7.38 (−9.23%) |
Apr 3, 2026 26w ago | 8-K | $8.46 $7.84 | ▼ −7.33% | ▼ −16.31% | $7.38 (−12.77%) |
Mar 27, 2026 27w ago | Press Release | $7.79 $8.13 | ▲ +4.36% | ▼ −8.38% | $7.38 (−5.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access